ALK is altered in 2.5% of malignant central nervous system neoplasm patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ALK status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

ATM is altered in 4.49% of malignant central nervous system neoplasm patients [2].

ATM is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain ATM status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

ATR is altered in 2.44% of malignant central nervous system neoplasm patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

BARD1 is altered in 1.71% of malignant central nervous system neoplasm patients [2].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is altered in 7.92% of malignant central nervous system neoplasm patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 is altered in 2.5% of malignant central nervous system neoplasm patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRCA2 is altered in 4.26% of malignant central nervous system neoplasm patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

BRIP1 is altered in 2.05% of malignant central nervous system neoplasm patients [2].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK12 is altered in 1.33% of malignant central nervous system neoplasm patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK1 is altered in 0.62% of malignant central nervous system neoplasm patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CHEK2 is altered in 1.32% of malignant central nervous system neoplasm patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is altered in 1.38% of malignant central nervous system neoplasm patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is altered in 2.88% of malignant central nervous system neoplasm patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCB is altered in 0.8% of malignant central nervous system neoplasm patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCC is altered in 1.08% of malignant central nervous system neoplasm patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCD2 is altered in 7.93% of malignant central nervous system neoplasm patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCE is altered in 1.57% of malignant central nervous system neoplasm patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCF is altered in 0.77% of malignant central nervous system neoplasm patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCG is altered in 1.43% of malignant central nervous system neoplasm patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCI is altered in 3.26% of malignant central nervous system neoplasm patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCL is altered in 1.04% of malignant central nervous system neoplasm patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCM is altered in 4.15% of malignant central nervous system neoplasm patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is altered in 3.49% of malignant central nervous system neoplasm patients [2].

H3F3A is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MCPH1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM2 is altered in 3.75% of malignant central nervous system neoplasm patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 3.05% of malignant central nervous system neoplasm patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MRE11A is altered in 1.27% of malignant central nervous system neoplasm patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

NBN is altered in 1.21% of malignant central nervous system neoplasm patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NBN status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is altered in 1.7% of malignant central nervous system neoplasm patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is altered in 1.95% of malignant central nervous system neoplasm patients [2].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is altered in 20.51% of malignant central nervous system neoplasm patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is altered in 1.72% of malignant central nervous system neoplasm patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51 is altered in 1.45% of malignant central nervous system neoplasm patients [2].

RAD51 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51B is altered in 0.45% of malignant central nervous system neoplasm patients [2].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD51C is altered in 0.84% of malignant central nervous system neoplasm patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD51D is altered in 0.71% of malignant central nervous system neoplasm patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

RAD54L is altered in 0.63% of malignant central nervous system neoplasm patients [2].

RAD54L is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD54L status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RET is altered in 2.75% of malignant central nervous system neoplasm patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RET status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ROS1 is altered in 3.69% of malignant central nervous system neoplasm patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

SLX4 is altered in 2.87% of malignant central nervous system neoplasm patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is altered in 3.46% of malignant central nervous system neoplasm patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCB1 is altered in 1.32% of malignant central nervous system neoplasm patients [2].

SMARCB1 is an inclusion eligibility criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain SMARCB1 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

TET2 is altered in 3.33% of malignant central nervous system neoplasm patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].